196 related articles for article (PubMed ID: 34809504)
1. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
3. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
4. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
5. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
6. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
Sola-Morales O; Curtis LH; Heidt J; Walsh L; Casso D; Oliveria S; Saunders-Hastings P; Song Y; Mercado T; Zusterzeel R; Mastey V; Harnett J; Quek RGW
Clin Pharmacol Ther; 2023 Aug; 114(2):325-355. PubMed ID: 37079433
[TBL] [Abstract][Full Text] [Related]
7. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
Jaksa A; Louder A; Maksymiuk C; Vondeling GT; Martin L; Gatto N; Richards E; Yver A; Rosenlund M
Value Health; 2022 Dec; 25(12):1967-1976. PubMed ID: 35760714
[TBL] [Abstract][Full Text] [Related]
9. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
10. Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?
Wolters S; Jansman FGA; Postma MJ
Value Health; 2022 Dec; 25(12):1958-1966. PubMed ID: 35752535
[TBL] [Abstract][Full Text] [Related]
11. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
12. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
14. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
15. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
Ling K; Qin H; Feng Y; Che H; Ding J; Li W
Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
[TBL] [Abstract][Full Text] [Related]
16. The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
Lux MP; Ciani O; Dunlop WCN; Ferris A; Friedlander M
Cancer Manag Res; 2021; 13():8457-8471. PubMed ID: 34795526
[TBL] [Abstract][Full Text] [Related]
17. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
18. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
Schaefer R; Hernandez D; Selberg L; Schlander M
J Comp Eff Res; 2021 Nov; 10(16):1187-1195. PubMed ID: 34583534
[No Abstract] [Full Text] [Related]
20. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
